Early experience with (68)Ga-DOTATATE preparation

Area of Science:

• Oncology
• Nuclear Medicine
• Radiochemistry

Background:

• Neuroendocrine tumors (NETs) are rare malignancies.
• NETs often overexpress somatostatin receptors (SSTRs) on their cell membranes.
• Radiolabeled peptides targeting SSTRs enable in vivo histopathological assessment.

Purpose of the Study:

• To evaluate the diagnostic performance of 68Ga-DOTATATE PET imaging for neuroendocrine tumors (NETs).
• To compare 68Ga-DOTATATE with other imaging modalities for NETs.
• To assess the feasibility of routine clinical application of 68Ga-DOTATATE PET.

Main Methods:

• Positron Emission Tomography (PET) imaging using 68Ga-DOTATATE.
• Comparison with other radiotracers like 18F-FDG, 111In-DTPA-octreotide, and 18F-DOPA.
• Evaluation in a cohort of 6 known NET cases.

Main Results:

• 68Ga-DOTATATE demonstrated higher sensitivity for low-grade and well-differentiated NETs compared to 18F-FDG.
• It proved superior to 111In-DTPA-octreotide and 18F-DOPA in evaluating metastatic, well-differentiated NETs.
• The imaging detected all known NET sites and identified a previously unknown peritoneal metastasis.

Conclusions:

• 68Ga-DOTATATE PET is a highly sensitive and effective tool for diagnosing and staging neuroendocrine tumors.
• Its superior performance in well-differentiated metastatic NETs supports its clinical utility.
• Further regulatory consideration is warranted for routine clinical implementation.